Structured financial advisory for biotech businesses navigating long R&D cycles, complex regulatory pathways, and capital-intensive commercialisation.
Industry Overview
The Bio-Technology sector spans agricultural biotech, industrial enzymes, biopharmaceuticals, diagnostics, contract research, and synthetic biology — each requiring significant capital investment across multi-year development cycles before any commercial revenue materialises. Backed by institutions like BIRAC, DBT, and DPIIT-recognised start-up frameworks, the sector is growing rapidly but remains chronically underfunded through conventional banking channels that are not built for asset-light, IP-driven businesses.
The central financial challenge for biotech businesses is timing: R&D spend peaks years before commercialisation, regulatory approvals under CDSCO, FSSAI, or international equivalents are non-linear and unpredictable, and lenders struggle to value IP, pipeline assets, or licensing agreements on a balance sheet. Most banks apply manufacturing credit norms to biotech businesses, consistently undervaluing their fundable assets and misunderstanding their revenue model — resulting in either rejection or heavily collateral-loaded loan structures that do not fit the business.
Arthasetu Fin Hub works with biotech companies at commercialisation stage, CROs, diagnostics manufacturers, and agri-biotech businesses to identify the right funding structures — whether that is structured debt from NBFCs and DFIs, pre-IPO fundraising advisory, or credit rating preparation for market access. We bridge the gap between what lenders think biotech businesses are worth and what they are actually building.
Sector Challenges
Biotech businesses routinely spend three to seven years on research and regulatory clearance before the first commercial sale. Conventional debt instruments — structured around 12 to 36-month repayment horizons — are fundamentally mismatched to this cycle, making most bank products unsuitable without significant structural adaptation.
Banks trained to assess collateral against fixed assets struggle to evaluate patents, licensing agreements, clinical data packages, and regulatory filings as fundable security. This results in blanket collateral demands that most asset-light biotech businesses cannot meet — regardless of the quality of their science or commercial potential.
CDSCO, FSSAI, and international regulatory timelines are difficult to predict with precision. Delays in approval extend the pre-revenue period unexpectedly, creating cash flow gaps that can destabilise even well-funded businesses if their debt structure does not include adequate flexibility and contingency planning.
How We Help
We structure debt facilities with NBFCs and specialised lenders who understand biotech business models — building in moratorium periods, milestone-linked drawdowns, and repayment flexibility that conventional bank products do not offer.
Explore ServiceFor biotech companies approaching commercialisation or seeking growth capital before a public listing, we provide financial restructuring, compliance preparation, and investor readiness advisory to position the business for a successful fundraise.
Explore ServiceWe prepare the financial documentation, business case, and rating presentation needed to secure a credible credit rating — improving lender confidence and opening access to better borrowing terms from banks and institutional investors.
Explore ServiceWe provide end-to-end financial advisory for manufacturing scale-up projects, pilot plant commissioning, and CRO capacity expansion — from detailed project reports through to DFI and bank funding coordination.
Explore ServiceWhy Arthasetu
We do not apply manufacturing credit templates to biotech businesses. Moratorium periods, milestone-linked debt drawdowns, and non-standard collateral structures are built into every advisory engagement.
Our coordination extends to NBFCs, development finance institutions, and specialised lenders with genuine understanding of IP-driven businesses — not just conventional banks applying standard industrial credit norms.
For businesses approaching investor readiness or public markets, we provide financial structuring, compliance preparation, and pitch advisory that positions the business credibly for pre-IPO rounds or public listing.
From CMA data, financial projections, and R&D capitalisation treatment to lender presentations and term negotiations, we handle the financial groundwork so your leadership team stays focused on science and market development.
Get Started
Talk to Arthasetu's advisors about structuring funding that matches your pipeline stage, regulatory timeline, and long-term commercialisation roadmap.
Manufacturing Sector